Join our daily newsletter At The Bell to receive exclusive market insights
- Atomo Diagnostics (AT1) receives approval for its COVID-19 rapid antigen test in New Zealand.
- The test was authorised by the New Zealand Ministry of Health under the New Zealand COVID-19 Public Health Response 2020 Order
- The authorisation covers professional and self-test use
- Hospitals, government agencies, healthcare workers, businesses, and pharmacies are all permitted to supply, distribute, and sell the test
- Shares are charging 17.5 per cent higher today 23.5 cents each
Atomo Diagnostics (AT1) has received approval for its COVID-19 rapid antigen test in New Zealand.
The test was authorised by the New Zealand Ministry of Health under the New Zealand COVID-19 Public Health Response 2020 Order.
The authorisation covers professional and self-test use.
NZ District Health Board hospitals, Government agencies, the healthcare workforce, New Zealand-based businesses and pharmacies are all permitted to supply, distribute, and sell the test.
In October, the company renegotiated its supply agreement with US manufacturer Access Bio providing the right, but not the obligation, for Atomo to purchase up to 20 million COVID-19 rapid antigen tests at a fixed price per unit during CY22.
Managing Director John Kelly said he is thrilled with the approval.
“We are excited the Atomo antigen test has received approval for use in New Zealand and we have now commenced commercial discussions related to supply of the product to the New Zealand market,” he said.
Shares were charging 17.5 per cent higher today 23.5 cents each at 12:32 pm AEDT.
